Want to see SCYX full AI Analyst Report?
SCYX Stock Chart & Stats
$5.67
-$0.16(-4.29%)
At close: 4:00 PM EDT
$5.67
-$0.16(-4.29%)
Day’s Range― - ―
52-Week Range$3.53 - $10.48
Previous Close$3.57
Volume103.76K
Average Volume (3M)90.26K
Market Cap
$48.16M
Enterprise Value-$4.09
Total Cash (Recent Filing)$54.08M
Total Debt (Recent Filing)$1.95M
Price to Earnings (P/E)―
Beta1.36
Next Earnings
Nov 11, 2026EPS Estimate
-0.72Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.84
Shares Outstanding9,949,609
10 Day Avg. Volume41,678
30 Day Avg. Volume90,256
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)0.64
Price to Sales (P/S)1.53
P/FCF Ratio-5.98
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$17.50Price Target Upside208.64% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-2.47
Revenue Forecast (FY)$1.25M
Bulls Say, Bears Say
Bulls Say
Conservative LeverageVery low leverage gives SCYNEXIS greater financial flexibility while it develops and commercializes its antifungal assets. A stronger equity base reduces near-term solvency pressure and leaves more room to fund operations or pursue strategic priorities without relying heavily on debt.
Differentiated Antifungal PlatformA therapy offering both oral and intravenous administration can address different treatment settings, while targeting serious fungal infections supports a focused commercial strategy. This product profile provides a durable platform for commercialization and potential licensing activity across relevant markets.
Strengthened Financial LeadershipThe CFO transition adds an executive with finance and business-development experience across biopharmaceutical companies. Stronger capital-markets and transaction capabilities could improve execution around funding, partnerships, and advancing SCYNEXIS’s antifungal and rare-disease pipeline.
Bears Say
Persistent UnprofitabilityLarge ongoing operating and net losses indicate that the business has not yet demonstrated durable earnings power. Continued negative margins can erode the equity base over time and make future growth increasingly dependent on successful commercialization, licensing, or external financing.
Negative Cash GenerationSCYNEXIS is currently consuming cash rather than funding operations internally, which raises execution and financing risk as development and commercialization continue. Although cash flow improved versus 2024, the reversal from positive 2023 generation shows that self-funding capacity remains inconsistent.
Revenue Volatility And Dilution CapacitySharp revenue deterioration weakens the commercial foundation needed to absorb ongoing costs and support profitability. At the same time, expanded authorized shares and equity-plan capacity increase the company’s ability to raise capital or issue compensation, creating potential dilution for existing shareholders.
SCYNEXIS News
SCYX FAQ
What was SCYNEXIS’s price range in the past 12 months?
SCYNEXIS lowest stock price was $3.53 and its highest was $10.48 in the past 12 months.
What is SCYNEXIS’s market cap?
SCYNEXIS’s market cap is $48.16M.
When is SCYNEXIS’s upcoming earnings report date?
SCYNEXIS’s upcoming earnings report date is Nov 11, 2026 which is in 58 days.
How were SCYNEXIS’s earnings last quarter?
SCYNEXIS released its earnings results on Aug 10, 2026. The company reported $0.63 earnings per share for the quarter, beating the consensus estimate of -$0.507 by $1.137.
Is SCYNEXIS overvalued?
According to Wall Street analysts SCYNEXIS’s price is currently Undervalued.
Does SCYNEXIS pay dividends?
SCYNEXIS does not currently pay dividends.
What is SCYNEXIS’s EPS estimate?
SCYNEXIS’s EPS estimate is -0.72.
How many shares outstanding does SCYNEXIS have?
SCYNEXIS has 9,949,609 shares outstanding.
What happened to SCYNEXIS’s price movement after its last earnings report?
SCYNEXIS reported an EPS of $0.63 in its last earnings report, beating expectations of -$0.507. Following the earnings report the stock price went down -6.208%.
Which hedge fund is a major shareholder of SCYNEXIS?
Currently, no hedge funds are holding shares in SCYX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
SCYNEXIS Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$17.50 (208.64% Upside)
$17.50 (208.64% Upside)
Blogger Sentiment
Bullish
SCYX Sentiment 100%
Sector Average 62%
Sector Average 62%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 10.8%
Last 30 Days ▼ 10.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-48.72%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
23.52%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
SCYNEXIS
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.
SCYX Stock 12 Month Forecast
Average Price Target
$17.50
▲(208.64% Upside)
Technical Analysis
Rockwell Med
―
TherapeuticsMD
―
Aytu BioScience
―
Cumberland Pharmaceuticals
―
IM Cannabis Corp
―
Ownership Overview
24.02% Insiders
19.44% Mutual Funds
42.37% Other Institutional Investors
9.70% Public Companies and
Individual Investors